UPCOMING EVENT
Cell & Gene Meeting on the Mediterranean
Location: Rome, Italy & Online
Apr. 15, 2025
FIND OUT MORE
Location: Rome, Italy & Online
Apr. 15, 2025
FIND OUT MORE
Our full sector data breakdown for Q4 2024 is now available! The data provide key insights into clinical trials, developers, and investment.
Tissue engineering and therapeutics are revolutionizing medicine by bridging the gap between biologics, cell therapy, and MedTech. ARM’s latest industry brief highlights the current state of this cutting-edge industry by highlighting.
Watch a full recording of the event, including ARM's Industry Update which reviews the current state of cell and gene therapy commercialization.
A recap of 2024’s milestones and an early picture of what could potentially be in store for the 2025 clinical pipeline of cell and gene therapies.
Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.
Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders.
ARM is the global voice of the cell and gene therapy sector, representing more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis.